Truist Securities Maintains Buy on BeOne Medicines, Raises Price Target to $420

Benzinga Newsdesk www.benzinga.com Positive 84.5%

Neg 0% Neu 0% Pos 84.5%

Truist Securities analyst Gregory Renza maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $418 to $420.